Meta-analysis of cognitive functioning in breast cancer survivors previously treated with standard-dose chemotherapy

Journal of Clinical Oncology

Volumn 30, Issue 29, 2012, Pages 3578-3587

  Jim, Heather S L ^a   Phillips, Kristin M ^a   Chait, Sari ^d   Faul, Leigh Anne ^e   Popa, Mihaela A ^c   Lee, Yun Hsiang ^f   Hussin, Mallory G ^a   Jacobsen, Paul B ^a   Small, Brent J ^a,b  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF SOUTH FLORIDA   (United States)

^c Biovest International   (United States)

^d Veterans Affairs Boston Healthcare Center   (United States)

^e GEORGETOWN UNIVERSITY   (United States)

^f NATIONAL TAIWAN UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; AROMATASE INHIBITOR; TAMOXIFEN;

ARTICLE; ATTENTION; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER SURVIVOR; COGNITION; COGNITIVE DEFECT; DEPTH PERCEPTION; EXECUTIVE FUNCTION; HUMAN; INFORMATION PROCESSING; LONGITUDINAL STUDY; META ANALYSIS; MOTOR PERFORMANCE; NEUROPSYCHOLOGICAL TEST; PRIORITY JOURNAL; RESPONSE TIME; SYSTEMATIC REVIEW; VERBAL BEHAVIOR; VERBAL MEMORY; VISUAL MEMORY;

ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; COGNITION; COGNITION DISORDERS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MIDDLE AGED; NEOADJUVANT THERAPY; NEUROPSYCHOLOGICAL TESTS; PREVALENCE; PROGNOSIS; RISK ASSESSMENT; SURVIVORS;

EID: 84867610331     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2011.39.5640     Document Type: Article

References (64)

1. Gross J: Chemotherapy fog is no longer ignored as illusion. New York Times, April 29, 2007, http://www.nytimes.com/2007/04/29/health/29chemo.html?-r= 2&pagewanted=all
2. American Cancer Society: Chemo brain: It is real. http://www.cancer.org/ Cancer/News/ExpertVoices/post/2012/04/09/Chemo-Brain-It-is-Real.aspx
3. Baker F, Denniston M, Smith T, et al: Adult cancer survivors: How are they faring? Cancer 104:2565-2576, 2005 (Pubitemid 41691539)
4. Brezden CB, Phillips KA, Abdolell M, et al: Cognitive function in breast cancer patients receiving adjuvant chemotherapy. J Clin Oncol 18:2695-2701, 2000 (Pubitemid 30463551)
5. Tchen N, Juffs HG, Downie FP, et al: Cognitive function, fatigue, and menopausal symptoms in women receiving adjuvant chemotherapy for breast cancer. J Clin Oncol 21:4175-4183, 2003 (Pubitemid 46606186)
6. Janelsins MC, Kohli S, Mohile SG, et al: An update on cancer- and chemotherapy-related cognitive dysfunction: Current status. Semin Oncol 38:431-438, 2011
7. Wefel JS, Saleeba AK, Buzdar AU, et al: Acute and late onset cognitive dysfunction associated with chemotherapy in women with breast cancer. Cancer 116:3348-3356, 2010
8. Ahles TA, Saykin AJ, McDonald BC, et al: Longitudinal assessment of cognitive changes associated with adjuvant treatment for breast cancer: Impact of age and cognitive reserve. J Clin Oncol 28:4434-4440, 2010
9. Jim HS, Donovan KA, Small BJ, et al: Cognitive functioning in breast cancer survivors: A controlled comparison. Cancer 115:1776-1783, 2009
10. Donovan KA, Small BJ, Andrykowski MA, et al: Cognitive functioning after adjuvant chemotherapy and/or radiotherapy for early-stage breast carcinoma. Cancer 104:2499-2507, 2005 (Pubitemid 41691574)
11. Schagen SB, Muller MJ, Boogerd W, et al: Change in cognitive function after chemotherapy: A prospective longitudinal study in breast cancer patients. J Natl Cancer Inst 98:1742-1745, 2006 (Pubitemid 44942713)
12. Collins B, Mackenzie J, Stewart A, et al: Cognitive effects of chemotherapy in post-menopausal breast cancer patients 1 year after treatment. Psychooncology 18:134-143, 2009
13. Mehnert A, Scherwath A, Schirmer L, et al: The association between neuropsychological impairment, self-perceived cognitive deficits, fatigue and health related quality of life in breast cancer survivors following standard adjuvant versus high-dose chemotherapy. Patient Educ Couns 66:108-118, 2007 (Pubitemid 46366616)
14. Anderson-Hanley C, Sherman ML, Riggs R, et al: Neuropsychological effects of treatments for adults with cancer: A meta-analysis and review of the literature. J Int Neuropsychol Soc 9:967-982, 2003 (Pubitemid 37428441)
15. Jansen CE, Miaskowski C, Dodd M, et al: A metaanalysis of studies of the effects of cancer chemotherapy on various domains of cognitive function. Cancer 104:2222-2233, 2005 (Pubitemid 41579970)
16. Falleti MG, Sanfilippo A, Maruff P, et al: The nature and severity of cognitive impairment associated with adjuvant chemotherapy in women with breast cancer: A meta-analysis of the current literature. Brain Cogn 59:60-70, 2005 (Pubitemid 41405841)
17. Stewart A, Bielajew C, Collins B, et al: A meta-analysis of the neuropsychological effects of adjuvant chemotherapy treatment in women treated for breast cancer. Clin Neuropsychol 20:76-89, 2006
18. Liberati A, Altman DG, Tetzlaff J, et al: The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: Explanation and elaboration. PLoS Med 6:e1000100, 2009
19. Hedges LV, Olkin I: Statistical Methods for Meta-Analysis. San Diego, CA, Academic Press, 1985
20. Borenstein M, Hedges LV, Higgins JPT, et al: Introduction to Meta-Analysis. Chichester, West Sussex, UK, John Wiley & Sons, 2009
21. Biostat: Comprehensive Meta Analysis v. 2.2.057. Tampa Bay, FL, Biostat, 2010
22. Schilder CM, Seynaeve C, Beex LV, et al: Effects of tamoxifen and exemestane on cognitive functioning of postmenopausal patients with breast cancer: Results from the neuropsychological side study of the tamoxifen and exemestane adjuvant multinational trial. J Clin Oncol 28:1294-1300, 2010
23. Duval S, Tweedie R: Trim and fill: A simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis. Biometrics 56:455-463, 2000 (Pubitemid 30422636)
24. Duval S, Tweedie R: A nonparametric 'trim and fill' method of accounting for publication bias in meta-analysis. J Am Stat Assoc 95:89-98, 2000
25. Orwin RG: A failsafe N for effect size in meta-analysis. J Ed Stat 8:157-159, 1983
26. Biglia N, Moggio G, Peano E, et al: Effects of surgical and adjuvant therapies for breast cancer on sexuality, cognitive functions, and body weight. J Sex Med 7:1891-1900, 2010
27. de Ruiter MB, Reneman L, Boogerd W, et al: Cerebral hyporesponsiveness and cognitive impairment 10 years after chemotherapy for breast cancer. Hum Brain Mapp 32:1206-1219, 2011
28. Jansen CE, Cooper BA, Dodd MJ, et al: A prospective longitudinal study of chemotherapy-induced cognitive changes in breast cancer patients. Support Care Cancer 19:1647-1656, 2011
29. Jenkins V, Shilling V, Deutsch G, et al: A 3-year prospective study of the effects of adjuvant treatments on cognition in women with early stage breast cancer. Br J Cancer 94:828-834, 2006
30. Kvale E, Clay O, Ross-Meadows L, et al: Cognitive speed of processing and functional declines in older cancer survivors: An analysis of data from the ACTIVE trial. Eur J Cancer Care (Engl) 19:110-117, 2010
31. Noal S, Levy C, Hardouin A, et al: One-year longitudinal study of fatigue, cognitive functions, and quality of life after adjuvant radiotherapy for breast cancer. Int J Radiat Oncol Biol Phys 81:795-803, 2011
32. Pedersen AD, Rossen P, Mehlsen MY, et al: Long-term cognitive function following chemotherapy in patients with testicular cancer. J Int Neuropsychol Soc 15:296-301, 2009
33. Schagen SB, Boogerd W, Muller MJ, et al: Cognitive complaints and cognitive impairment following BEP chemotherapy in patients with testicular cancer. Acta Oncol 47:63-70, 2008
34. Schagen SB, Hamburger HL, Muller MJ, et al: Neurophysiological evaluation of late effects of adjuvant high-dose chemotherapy on cognitive function. J Neurooncol 51:159-165, 2001 (Pubitemid 32435496)
35. Schagen SB, Muller MJ, Boogerd W, et al: Late effects of adjuvant chemotherapy on cognitive function: A follow-up study in breast cancer patients. Ann Oncol 13:1387-1397, 2002
36. Schagen SB, van Dam FS, Muller MJ, et al: Cognitive deficits after postoperative adjuvant chemotherapy for breast carcinoma. Cancer 85:640-650, 1999 (Pubitemid 29075285)
37. Scherwath A, Mehnert A, Schleimer B, et al: Neuropsychological function in high-risk breast cancer survivors after stem-cell supported high-dose therapy versus standard-dose chemotherapy: Evaluation of long-term treatment effects. Ann Oncol 17:415-423, 2006 (Pubitemid 43329577)
38. Shilling V, Jenkins V: Self-reported cognitive problems in women receiving adjuvant therapy for breast cancer. Eur J Oncol Nurs 11:6-15, 2007
39. Silverman DH, Dy CJ, Castellon SA, et al: Altered frontocortical, cerebellar, and basal ganglia activity in adjuvant-treated breast cancer survivors 5-10 years after chemotherapy. Breast Cancer Res Treat 103:303-311, 2007 (Pubitemid 46944511)
40. Skaali T, Fosså SD, Andersson S, et al: Self-reported cognitive problems in testicular cancer patients: Relation to neuropsychological performance, fatigue, and psychological distress. J Psychosom Res 70:403-410, 2011
41. Small BJ, Rawson KS, Walsh E, et al: Catechol-O-methyltransferase genotype modulates cancer treatment-related cognitive deficits in breast cancer survivors. Cancer 117:1369-1376, 2011
42. Tager FA, McKinley PS, Schnabel FR, et al: The cognitive effects of chemotherapy in postmenopausal breast cancer patients: A controlled longitudinal study. Breast Cancer Res Treat 123:25-34, 2010
43. van Dam FS, Schagen SB, Muller MJ, et al: Impairment of cognitive function in women receiving adjuvant treatment for high-risk breast cancer: High-dose versus standard-dose chemotherapy. J Natl Cancer Inst 90:210-218, 1998
44. Whitney KA, Lysaker PH, Steiner AR, et al: Is "chemobrain" a transient state? A prospective pilot study among persons with non-small cell lung cancer. J Support Oncol 6:313-321, 2008
45. Yamada TH, Denburg NL, Beglinger LJ, et al: Neuropsychological outcomes of older breast cancer survivors: Cognitive features ten or more years after chemotherapy. J Neuropsychiatry Clin Neurosci 22:48-54, 2010
46. Ahles TA, Saykin AJ, Furstenberg CT, et al: Neuropsychologic impact of standard-dose systemic chemotherapy in long-term survivors of breast cancer and lymphoma. J Clin Oncol 20:485-493, 2002 (Pubitemid 34072533)
47. Ahles TA, Saykin AJ, Noll WW, et al: The relationship of APOE genotype to neuropsychological performance in long-term cancer survivors treated with standard dose chemotherapy. Psychooncology 12:612-619, 2003 (Pubitemid 37086736)
48. Bender CM, Sereika SM, Berga SL, et al: Cognitive impairment associated with adjuvant therapy in breast cancer. Psychooncology 15:422-430, 2006 (Pubitemid 43826855)
49. Castellon SA, Ganz PA, Bower JE, et al: Neurocognitive performance in breast cancer survivors exposed to adjuvant chemotherapy and tamoxifen. J Clin Exp Neuropsychol 26:955-969, 2004 (Pubitemid 39577316)
50. Wefel JS, Lenzi R, Theriault RL, et al: The cognitive sequelae of standard-dose adjuvant chemotherapy in women with breast carcinoma. Cancer 100:2292-2299, 2004
51. Hensley ML, Correa DD, Thaler H, et al: Phase I/II study of weekly paclitaxel plus carboplatin and gemcitabine as first-line treatment of advanced-stage ovarian cancer: Pathologic complete response and longitudinal assessment of impact on cognitive functioning. Gynecol Oncol 102:270-277, 2006 (Pubitemid 44063582)
52. Inagaki M, Yoshikawa E, Matsuoka Y, et al: Smaller regional volumes of brain gray and white matter demonstrated in breast cancer survivors exposed to adjuvant chemotherapy. Cancer 109:146-156, 2007 (Pubitemid 46120202)
53. Fan HG, Houédé-Tchen N, Yi QL, et al: Fatigue, menopausal symptoms, and cognitive function in women after adjuvant chemotherapy for breast cancer: 1- and 2-year follow-up of a prospective controlled study. J Clin Oncol 23:8025-8032, 2005 (Pubitemid 46657404)
54. Hurria A, Rosen C, Hudis C, et al: Cognitive function of older patients receiving adjuvant chemotherapy for breast cancer: A pilot prospective longitudinal study. J Am Geriatr Soc 54:925-931, 2006 (Pubitemid 43847029)
55. Yoshikawa E, Matsuoka Y, Inagaki M, et al: No adverse effects of adjuvant chemotherapy on hippocampal volume in Japanese breast cancer survivors. Breast Cancer Res Treat 92:81-84, 2005 (Pubitemid 40875082)
56. Lezak MD, Howieson DB, Loring DW: Neuropsychological Assessment (ed 4). New York, NY, Oxford University Press, 2004
57. Schagen SB, van Dam FS: Does cognitive impairment after chemotherapy for breast cancer improve over time or does practice make perfect? J Clin Oncol 24:5170-5171, 2006 (Pubitemid 46623205)
58. Collins B, Mackenzie J, Stewart A, et al: Cognitive effects of hormonal therapy in early stage breast cancer patients: A prospective study. Psychooncology 18:811-821, 2009
59. Palmer JL, Trotter T, Joy AA, et al: Cognitive effects of tamoxifen in pre-menopausal women with breast cancer compared to healthy controls. J Cancer Surviv 2:275-282, 2008
60. Hermelink K, Henschel V, Untch M, et al: Short-term effects of treatment-induced hormonal changes on cognitive function in breast cancer patients: Results of a multicenter, prospective, longitudinal study. Cancer 113:2431-2439, 2008
61. Phillips KM, Jim HS, Small BJ, et al: Cognitive functioning after cancer treatment: A 3-year longitudinal comparison of breast cancer survivors treated with chemotherapy or radiation and noncancer controls. Cancer 118:1925-1932, 2012
62. Ferguson RJ, Ahles TA, Saykin AJ, et al: Cognitive-behavioral management of chemotherapy-related cognitive change. Psychooncology 16:772-777, 2007 (Pubitemid 47249179)
63. Fardell JE, Vardy J, Johnston IN, et al: Chemotherapy and cognitive impairment: Treatment options. Clin Pharmacol Ther 90:366-376, 2011
64. Wefel JS, Vardy J, Ahles T, et al: International Cognition and Cancer Task Force recommendations to harmonise studies of cognitive function in patients with cancer. Lancet Oncol 12:703-708, 2011